Group 1 - Both ACVA and FRPT are expected to benefit from industry rebounds and new growth drivers over the next three years [1] - Recent growth deceleration has been noted, but the potential for future growth remains [1]

Core Viewpoint - Merck has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these new businesses by the mid-2030s as it accelerates the launch of additional drugs in anticipation of competition to its cancer therapy Keytruda [1] Group 1 - Merck forecasts $70 billion in revenue from new growth drivers by the mid-2030s [1] - The company is accelerating the launch of additional drugs [1] - This strategy is in response to looming competition for its blockbuster cancer therapy Keytruda [1]